Author

Ariadne Androulidaki

University of Cologne

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:statistical model· 1

Frequent Co-Authors

Filippo BeleggiaiD· 2 shared Julie GeorgeiD· 2 shared Silvia von KarstedtiD· 2 shared Agnieszka Rumińska· 1 shared Alexander QuaasiD· 1 shared Angelika Beate RiemeriD· 1 shared Anna Schmitt· 1 shared Anna SchöllhorniD· 1 shared

Activity by Year

2021-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Filippo BeleggiaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintApr 2, 2026

A targetable dependency on nonsense-mediated decay for proteostasis and immune control in small cell lung cancer

Lucia Torres Fernández, Volker Boehm, Joel Kaufmann…·Julie George

This study identifies NMD inhibition as a therapeutic strategy for SCLC by enhancing immunogenicity and improving immunotherapy efficacy through increased neoantigen presentation.

DOI 10.64898/2026.03.31.715503

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyNature CommunicationsPeer-reviewedApr 6, 2021

Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes

Christina Bebber, Emily Thomas, Zhiyi Chen…·Silvia von Karstedt

The paper identifies ferroptosis sensitivity as a distinguishing feature of non-neuroendocrine SCLC subtypes and shows that combining ferroptosis induction with TRX pathway inhibition can selectively kill both non-NE and NE SCLC tumors.

DOI 10.1038/s41467-021-22336-4

humanbulk RNA-seq

𝕏 PostBluesky